The findings of the present study further indicated that the administration of TMX, MTZ, and their combination markedly improved the course of RA, as evidenced by significant reductions in blood levels of serum fibrogenic biomarkers, including COMP, MMP-1, and MMP-3, compared to FCA-induced RA (Figure 9). The gene discussed is COMP; the disease is rheumatoid arthritis.